Navigation Links
Gene Network Sciences Names New CSO and Announces New Scientific Advisory Board

CAMBRIDGE, Mass., April 16 /PRNewswire/ -- Gene Network Sciences, Inc. (GNS) today announced the creation of the new position of Chief Scientific Officer and a newly constituted Scientific Advisory Board (SAB) of world class experts from both the biopharmaceutical industry and leading academic organizations.

GNS's first Chief Scientific Officer, Dr. James Collins, is Professor of Biomedical Engineering and University Professor at Boston University and co-director of Boston University's Center for Biodynamics. Collins is a MacArthur Fellow, an original Technology Review TR100 award recipient, a recipient of an NIH Director's Pioneer Award, and a Rhodes Scholar. Professor Collins will also co-chair GNS's Scientific Advisory Board. He is the founder and former CSO of Cellicon Biotechnologies, a leading systems biology company, and Afferent Corporation, a medical device company.

"Professor Collins' broad experience as a scientific leader in systems biology and the reverse-engineering of genetic networks makes him uniquely qualified to lead GNS's scientific efforts," said Colin Hill, President and Chief Executive Office of GNS.

"During the past year, GNS has made important advances in the validation of its technology," said Collins. "In addition to discovering drug mechanism of action and biomarkers used by its pharma partners in clinical development, GNS's formation of discovery alliances with leading academic clinics and its discovery of potential therapeutic targets ab initio from human data has established GNS as a unique computational biology company."

Supporting Collins in his new role as CSO of GNS is a newly constituted Scientific Advisory Board that brings expertise in key areas that will be invaluable in evolving GNS's discovery engine and advancing GNS's pipeline of gene network based targets and diagnostics programs from discovery to market. Members of the new SAB are leading pharmaceutical executives and academic systems biology pioneers with significant pharmaceutical drug discovery and development experience.
In addition to Professor Collins, the members of the SAB include:

* Jeffrey Besterman, Ph.D., Executive Vice President of Research &

Development and Chief Scientific Officer, Methylgene.

* Jeffrey Hanke, Ph.D., Vice President, Cancer Care Discovery,


* Stuart Kaufmann, M.D., Chair of Biocomplexity and Informatics,

University of Calgary. Dr. Kaufmann is the co-founder of Santa Fe

Institute, Darwin Molecular, BiosGroup, GenPathway, and is a

MacArthur Fellow.

* Hiroaki Kitano, Director of Sony Computer Science (Tokyo). Dr.

Kitano is the President of the Institute for Systems Biology and is

the visionary behind Aibo, the robotic dog.

* Christophe Lengauer, Ph.D., Executive Director, Cancer Discover,


* Matej Oresic, Ph.D., Principal Investigator, Systems Biology &

Bioinformatics, VTT Technical Research Center of Finland. Dr.

Oresic is the founder of Zora Biosciences and is the former head of

computational biology at BG Medicine.

* Hans Winkler, Ph.D., Senior Director, Functional Genomics, Johnson &


"We are very pleased to assemble these key thought leaders in pharma drug discovery and development together with the pioneers of systems biology to establish the GNS Scientific Advisory Board," said Hill. "Their deep understanding of how breakthrough technologies are leveraged in drug discovery and development will be instrumental in further advancing our REFS(TM) discovery platform and transitioning our scientific discoveries into potential therapeutics and diagnostics. Further, the commitment and direct participation of these world class scientist-executives on our SAB reflects the advances we've made extracting actionable knowledge directly from experimental data."

"This experienced SAB is well-positioned to make a significant contribution to GNS's continuing discovery operations and ultimate partnering of targets and diagnostics," said Collins.

About Gene Network Sciences

Founded in 2000, Gene Network Sciences ( is a leader in biosimulation with its ability to derive molecular mechanisms of drugs and diseases directly from molecular profiling and clinical data without any a priori knowledge. Based in Cambridge, Massachusetts, and Ithaca, New York, GNS uses its REFS(TM) (reverse engineering and forward simulation) technology in pharmaceutical and clinical settings to rapidly turn complex and heterogeneous data sets into cell and organ-level computer models of drug efficacy and drug safety. These models simulate the mechanisms of disease and clinical performance of drug candidates. By discovering how and why specific genes and drug candidates impact human biology, GNS technology enables the rapid development of breakthrough drug and diagnostic products.

SOURCE Gene Network Sciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Digital Unions RT1(TM) Software Creates Telegenetics Network for Region 3 Genetics Collaborative
2. Six UK Hospitals Join Together in Using Varian Medical Oncology Information Network
3. ThirdBiotech Networking Group Launches
4. Social Network for Scientists Marks Ten Years Online
5. BitWine (TM) Nutrition Advisors Network Expands Roster of Licensed Dietitians and Nutritionists
6. CorVel Corporation Medical Provider Network Adds New Providers to Increase Savings and Improve Access to Care
7. The Food Allergy & Anaphylaxis Network (FAAN) and Verus Pharmaceuticals Work Together to Raise Awareness of Food Allergies
8. Salugen to Present at Nutrition Capital Networks First In-Person Investor Meeting
9. Michigan Life Science Network to Form Two New Virtual Companies
10. CompareNetworks Media Group Delivers CME/CE Through Acuity Medical Education
11. Michigan Life Science Network: Virtual Companies Get Global Reception
Post Your Comments:
(Date:11/30/2015)... /PRNewswire/ - Zenith Epigenetics Corp. ("Zenith" or the "Company") today ... to its Board of Directors to replace Dr. ... wealth of experience as co-founder of Resverlogix, with expertise in ... --> --> Dr. Wong remarked, "I am ... Zenith,s long standing expertise in epigenetics and the advanced stage ...
(Date:11/30/2015)... Atlanta, GA (PRWEB) , ... November 30, 2015 ... ... announced a new globally touring exhibition Jurassic World: The Exhibition, opening in March ... Exhibition will embark on a worldwide tour including several North American tour dates. ...
(Date:11/30/2015)... 30, 2015 Human Longevity, Inc. (HLI), the ... acquired Cypher Genomics, Inc., a leading genome informatics company ... software solutions. The San Diego -based ... Cypher CEO and Co-founder, Ashley Van Zeeland , Ph.D., ...  Financial details of the deal were not disclosed. ...
(Date:11/30/2015)... SAN DIEGO , Nov. 30, 2015  HUYA ... China,s pharmaceutical innovations, today announced ... Korea Drug Development Fund (KDDF) to foster collaboration between ... Korean development and commercialization of healthcare products for the ... potential as an important source of new innovative preclinical ...
Breaking Biology Technology:
(Date:11/4/2015)... , November 4, 2015 ... new market report published by Transparency Market Research "Home Security ... Trends and Forecast 2015 - 2022", the global home security ... 30.3 bn by 2022. The market is estimated to ... period from 2015 to 2022. Rising security needs among ...
(Date:10/29/2015)... Va. , Oct. 29, 2015 Daon, ... today that it has released a new version of ... customers in North America have ... IdentityX v4.0 also includes a FIDO UAF certified ... are already preparing to activate FIDO features. These customers ...
(Date:10/29/2015)... 2015 Today, LifeBEAM , a ... 2XU, a global leader in technical performance sports ... with advanced bio-sensing technology. The hat will allow ... key biometrics to improve overall training performance. As ... will bring together the most advanced technology, extensive ...
Breaking Biology News(10 mins):